Monofer Dosing for CKD Stage 5
For CKD Stage 5 patients weighing ≥50 kg, administer Monofer 1000 mg as a single intravenous infusion over at least 20 minutes; for patients <50 kg, give 20 mg/kg over at least 20 minutes. 1
Dosing Algorithm
Initial Dosing
- Patients ≥50 kg: 1000 mg IV infusion over ≥20 minutes as single dose
- Patients <50 kg: 20 mg/kg IV infusion over ≥20 minutes as single dose
- Repeat dose when iron deficiency anemia recurs 1
Preparation
- Dilute in 100-500 mL of 0.9% sodium chloride (final concentration >1 mg iron/mL)
- Administer within 8 hours of dilution
- Do not mix with other medications 1
Clinical Context for CKD Stage 5
While the FDA label provides the specific dosing regimen above, understanding iron management in advanced CKD is crucial. Most hemodialysis patients (CKD Stage 5) require regular intravenous iron to maintain hemoglobin 11-12 g/dL and prevent functional iron deficiency. 2
Target Iron Parameters
- Transferrin saturation (TSAT) ≥20%
- Serum ferritin ≥100 ng/mL 2
These targets ensure adequate iron availability for erythropoiesis, particularly in patients receiving erythropoiesis-stimulating agents (ESAs).
Maintenance Therapy Considerations
For hemodialysis patients specifically, older guidelines suggest maintenance regimens of 250-1000 mg iron within 12 weeks, which can be administered weekly, biweekly, or with each dialysis session 2. However, Monofer's advantage is the ability to deliver 1000 mg in a single 20-minute infusion, making it more convenient than older formulations requiring multiple smaller doses 3.
Monitoring Requirements
- Monitor for hypersensitivity reactions during infusion and for at least 30 minutes post-infusion 1
- Check TSAT and ferritin every 3 months during maintenance phase 2
- Assess hemoglobin response to guide repeat dosing 1
Upper Safety Limits
- Withhold iron if TSAT >50% or ferritin >800 ng/mL 2
- Reassess iron parameters after 3 months before resuming therapy
- When restarting, reduce dose by one-third to one-half 2
Critical Safety Points
Personnel and therapies for treating serious hypersensitivity reactions must be immediately available before administering Monofer. 1 This is non-negotiable given the black box warning for hypersensitivity reactions, though serious reactions occurred in only 0.3% of patients in clinical trials 1.
Contraindications
- Prior serious hypersensitivity to Monofer or its components
- Iron overload 1
Common Pitfalls to Avoid
- Do not administer as rapid IV push - minimum 20 minutes required (unlike some older formulations that allowed faster administration) 1
- Monitor for extravasation - causes long-lasting brown discoloration 1
- Do not give test dose - unlike iron dextran, Monofer does not require test dosing 1
Comparative Context
Monofer (iron isomaltoside) has demonstrated comparable efficacy and safety to iron sucrose in hemodialysis patients, with the advantage of higher single-dose capacity (1000 mg vs 200 mg maximum for iron sucrose) 3. Studies show >82% of patients maintain hemoglobin in target range with either formulation, but Monofer produces significantly higher ferritin levels at weeks 1,2, and 4, and higher reticulocyte counts at week 1 3, suggesting more robust iron repletion.
The 2024 expert consensus supports administering 1000 mg LMWID (similar molecular weight iron preparations) as a single infusion, confirming this approach is both safe and convenient 4. Recent KDIGO 2026 guidelines emphasize more proactive iron supplementation thresholds for hemodialysis patients 5, 6, supporting the use of high-dose single infusions like Monofer's 1000 mg regimen.